Renal impairment, cardiovascular disease, and the short-term efficacy and safety of PCSK9 targeted by inclisiran

Author(s):: Zijlstra, L.E.; Trompet, S. (0000-0001-5006-0528); Mooijaart, S.P. (0000-0003-3106-3568); Buren, M. van; Jukema, J.W. (0000-0002-3246-8359)

Published: 2020
Publication type: Article / Letter to editor

Date issued: 2020-01-31
Language: English
Publisher: Elsevier
Is part of: Mayo Clinic Proceedings (2020), Vol. 95, no. 1, p. 12-14
hdl: 1887/3181440
doi: 10.1016/j.mayocp.2019.11.010
URL: https://www.sciencedirect.com/science/article/pii/S0025619619310055?via%3Dihub